Thanks HLL
Bit quite here today
PAB
PAT-SM6 to treat multiple myeloma
2 out of 8 patients have shown evidence of stable disease, analysed at day +35 post treatment.
Point to consider: Patients in this trial are resistant to all currently marketed drugs and have a large disease burden.
Next announcement traders are anticipating is the approval to commence administering PAT-SM6 to patients in cohort 4 where patients receive twice the dosage strength to those in the previous group.
3 patients per group, trial ends Q4 2013
Biotech $20M mc .....$5M cash at bank.
What did Big Pharma pay for a slice of the action in this space as recent as this week for a drug in a Phase 1b clinical trial.......
http://www.fiercebiotech.com/story/celgene-spends-100m-option-buy-myeloma-drug-developer-acetylon/2013-07-29
- Forums
- ASX - Day Trading
- daytrading august 1 pre-market
Thanks HLLBit quite here todayPAB PAT-SM6 to treat multiple...
-
- There are more pages in this discussion • 25 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)